Form 4: Passage Bio Director Derrell Porter Acquires Stock Options

Director Derrell Porter acquired 47,693 stock options in Passage Bio, Inc. on May 21, 2024.

Summary

• On May 21, 2024, Derrell Porter, a director of Passage Bio, Inc. (PASG), acquired 47,693 stock options.
• The options have an exercise price of $1.28.
• The options vest in full on the earlier of the one-year anniversary of the grant date or the date of the issuer's 2025 Annual Meeting of its stockholders, subject to continuous service.
• The expiration date for the options is May 21, 2034.
• Following the transaction, Porter directly owns 47,693 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing the acquisition of stock options, which is neither inherently positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule tied to the 2025 Annual Meeting suggests an expectation of continued service by the reporting person.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it aligns the director's interests with the company's performance.

Key Dates